Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada.
| Revenue (Most Recent Fiscal Year) | $1.00M |
| Net Income (Most Recent Fiscal Year) | $-41.52M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.50 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -152.42% |
| Return on Assets (Trailing 12 Months) | -48.40% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.10 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.10 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 4.06 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.19 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.67 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.68 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 53.46M |
| Free Float | 43.04M |
| Market Capitalization | $59.35M |
| Average Volume (Last 20 Days) | 1.57M |
| Beta (Past 60 Months) | 0.86 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.18% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |